MARVERTI, Gaetano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.698
EU - Europa 4.697
AS - Asia 1.087
SA - Sud America 20
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 1
Totale 14.517
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.656
GB - Regno Unito 1.489
IT - Italia 1.020
SE - Svezia 571
DE - Germania 514
CN - Cina 407
FR - Francia 283
SG - Singapore 229
UA - Ucraina 179
PL - Polonia 174
HK - Hong Kong 154
FI - Finlandia 131
TR - Turchia 107
BG - Bulgaria 85
IN - India 60
BE - Belgio 52
IE - Irlanda 52
CA - Canada 42
ID - Indonesia 37
LT - Lituania 35
RU - Federazione Russa 30
CZ - Repubblica Ceca 22
JP - Giappone 22
VN - Vietnam 20
KR - Corea 15
NL - Olanda 13
MY - Malesia 12
CH - Svizzera 11
BR - Brasile 9
TW - Taiwan 9
ES - Italia 8
RO - Romania 8
IR - Iran 7
CL - Cile 6
DK - Danimarca 6
GR - Grecia 6
AU - Australia 5
AR - Argentina 4
EU - Europa 4
NZ - Nuova Zelanda 4
AT - Austria 2
MO - Macao, regione amministrativa speciale della Cina 2
PH - Filippine 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BD - Bangladesh 1
BY - Bielorussia 1
CO - Colombia 1
EE - Estonia 1
NO - Norvegia 1
NP - Nepal 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TZ - Tanzania 1
Totale 14.517
Salva come PNG Salva come JPEG
Città #
Fairfield 1.252
Southend 1.185
Woodbridge 827
Chandler 796
Ashburn 737
Ann Arbor 540
Seattle 506
Houston 501
Cambridge 434
Wilmington 404
Nyköping 378
Jacksonville 372
Dearborn 358
Modena 270
Frankfurt am Main 207
Kraków 169
Hong Kong 146
New York 136
San Diego 120
Beijing 109
Singapore 105
Princeton 89
Sofia 84
Eugene 79
Fremont 77
Helsinki 73
Izmir 69
Dublin 49
Boardman 47
London 46
Brussels 43
Bologna 42
Redwood City 42
Shanghai 38
Jakarta 37
Parma 35
Des Moines 33
Grafing 28
Milan 27
Bremen 25
Ottawa 25
Norwalk 24
Falls Church 20
Hefei 20
Brno 19
Dong Ket 19
San Mateo 19
Guangzhou 16
Nanjing 16
Verona 16
Phoenix 14
Piacenza 14
Toronto 14
Washington 13
Augusta 12
Formigine 12
Munich 12
Rome 12
Auburn Hills 11
Kilburn 11
Kunming 11
Padova 10
Reggio Emilia 10
Ferrara 9
Los Angeles 9
Jinan 8
Osnabrück 8
Paris 8
Saint Petersburg 8
Argenta 7
Bangalore 7
Chiswick 7
Hounslow 7
Leuven 7
Turin 7
Boston 6
Finale Emilia 6
Monmouth Junction 6
Mountain View 6
Perugia 6
Romainville 6
Rossdorf 6
Sassuolo 6
Wuhan 6
Zurich 6
Amsterdam 5
Carovigno 5
Chicago 5
Detroit 5
Hebei 5
Indiana 5
Lappeenranta 5
Reggio Nell'emilia 5
San Francisco 5
San Giovanni Suergiu 5
San Giuliano Milanese 5
Taichung 5
Tokyo 5
Valby 5
Albinea 4
Totale 11.091
Salva come PNG Salva come JPEG
Nome #
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 326
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 296
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 279
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 260
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 254
Repurposing of drugs targeting yap-tead functions 248
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 247
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 238
Polyamine depletion protects HL-60 cells from 2-deoxy-D-ribose-induced apoptosis. 231
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 230
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 228
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 227
The effect of spermine on calcium requirement for protein kinase C association with phospholipid vesicles. 226
1H, 13C, 195Pt NMR study on platinum(II) interaction with sulphur containing Amadori compounds 226
Translational repression of thymidylate synthase by targeting its mRNA 225
Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine N-1-acetyltransferase expression 223
Spermidine/spermine N1-acetyltransferase transient over-expression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin 222
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 221
Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies 214
Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and-resistant human ovarian cancer cells 212
Modulation of cis-diamminedichloroplatinum(II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. 210
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 210
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 209
Newly synthesized curcumin derivatives: crosstalk between chemico-physical properties and biological activity. 203
Differential induction of spermidine/spermine N1-acetyltransferase activity in cisplatin-sensitive and -resistant ovarian cancer cells in response to N1,N12-bis (ethyl)spermine involves transcriptional and post-transcriptional regulation. 202
Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives 201
Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells 198
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 198
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 196
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 194
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 186
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 185
The 1,10-phenanthroline ligand enhances the antiproliferative activity of dna-intercalating thiourea-pd(Ii) and-pt(ii) complexes against cisplatin-sensitive and-resistant human ovarian cancer cell lines 184
Polyamine depletion switches the form of 2-deoxy-D-ribose-induced cell death from apoptosis to necrosis in HL-60 cells. 181
Inhibitor of Ovarian Cancer Cells growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase 177
N-(naphthyl)-N′-(methoxy carbonyl)thiocarbamide and its Cu(I) complex: synthesis, spectroscopic, X-ray, DFT andin vitrocytotoxicity study 177
Heat shock protein 90 and serine/threonine kinase B-Raf inhibitors have overlapping chemical space 175
Ligand-Based Virtual Screening and ADME-Tox Guided Approach to Identify Triazolo-quinoxalines as Folate Cycle Inhibitors. 175
2-Deoxy-D-ribose-induced apoptosis in HL-60 cells is associated with the cell cycle progression by spermidine 172
ANTICANCER DRUGS 170
N-1,N-12-bis(ethyl)spermine effect on growth of cis-diamminedichloroplatinum(II)-sensitive and -resistant human ovarian-carcinoma cell lines 170
A proteomic approach to investigate the mechanism of action of anticancer peptides 169
Depletion of Trichoplein (TpMs) Causes Chromosome Mis-Segregation, DNA Damage and Chromosome Instability in Cancer Cells 168
Spermine protects protein kinase C from phospholipid-induced inactivation 167
Chairperson EUTROC- Mayo Conference-Berlin - Preliminary characterization of pharmacodynamic biomarkers for LR-peptide growth inhibition of ovarian cancer (OC) cell models. 167
Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression 165
Monodentate Coordination of N, N′-Disubstituted Thiocarbamide Ligands: Syntheses, Structural Analyses, In Vitro Cytotoxicity and DNA Damage Studies of Cu(I) Complexes 160
Studies on the anti-proliferative effects of novel DNA-intercalating bipyridyl-thiourea-Pt(II) complexes against cisplatin-sensitive and -resistant human ovarian cancer cells 154
Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth 154
Invited lecture to 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine 10-12 October, 2013, Creta Maris, Hersonissos, Crete, Greece 154
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting 154
Effect of Spermine on Membrane-Associated and Membrane-Inserted Forms of Protein Kinase C 153
Copper (I) complexes based on novel N, N'-disubstituted thiocarbamides: Synthesis, spectroscopic, in vitro cytotoxicity, DNA damage and G0/G1 cell cycle arrest studies 151
Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer-US8916679 “B2 - Granted patent as second publication”. 149
Relationship Between Spermine and Calcium on the Activation Process of Protein Kinase C. 145
Synthesis, chemical and biological studies on new Fe3þ-glycosilated b-diketo complexes for the treatment of iron deficiency 144
Synthesis, molecular structure exploration and in vitro cytotoxicity screening of five novel N, N′- disubstituted thiocarbamide derivatives 144
Designing selective Cys-ligands to unpair the binding of the Human Transcription Enhancer Associated Domain 4 (hTEAD-4) with its modulators to halt cancer cell growth 143
Folate Receptor Expression and Folate Receptor Targeted Chemotherapy in Cisplatin-sensitive and – resistant Human cancer cell lines Marverti G.a, Pirondi S.a, MarracciniC.a, Frassineti C.a, Helleman J.b, Berns E.M.J.J. b, and Costi, M.P. cThe 4th International Symposium on Folate Receptors and Transporters Cozumel, Mexico October 7 - 11, 2012 135
Collateral sensitivity to novel folate cycle inhibitors enhances cisplatin effectiveness against human ovarian cancer cells. 132
Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer 132
Development of new metal-chelating multi target drus derived from Curcumin 132
Experimental and theoretical exploration of molecular structure and anticancer properties of two N, N′–disubstituted thiocarbamide derivatives 130
Synthesis, characterization, Hirshfeld surface, cytotoxicity, DNA damage and cell cycle arrest studies of N, N-diphenyl-N'-(biphenyl-4- carbonyl/4-chlorobenzoyl) thiocarbamides 130
Exploring the biological activity of a library of 1,2,5-Oxadiazole derivatives endowed with antiproliferative activity 129
SSAT modulation by putative regulators of folate cycle enzymes expression in cisplatin-sensitive and –resistant human ovarian cancer cell lines. 118
Effect of spermine on association of protein kinase C with phospholipid vesicles. 116
Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered responce in accumulation-defective resistant cells. 113
Copper (I) complexes of N-(2/4 methoxy/2-chloro-4-nitro) phenyl-N’ (methoxycarbonyl) thiocarbamides as potential anticancer agents: Synthesis, crystal structure, in vitro cytotoxicity and DNA damage studies. 110
Glucosyl curcuminoid derivatives: Fe(III) and Ga(III) chelating agents with anti-cancer properties 106
Synthesis, spectroscopic, crystal structure and in vitro cytotoxicity studies of N-thiophenoyl-N'-substituted phenyl thiocarbamide derivatives 106
Differential induction of spermidine/spermine N1-acetyltransferase in cisplatin-sensitive and -resistant human breast cancer cells by N1, N12-bis(ethyl)spermine. 105
Erratum: Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase (Proceedings of the National Academy of Sciences of the United States of America (2011) 108, 34 (E542-E549) DOI: 10.1073/pnas.1104829108) 100
Glucosyl curcuminoid derivatives: Fe(III) and Ga(III) chelating agents with anti-cancer properties 97
Effect of spermine on irreversible insertion of protein kinase C into phospholipid vesicles. 95
Effetto delle poliammine sulla regolazione della proteina cinasi C. 94
Structural bases for the synergistic inhibition of human thymidylate synthase and ovarian cancer cell growth by drug combinations 91
Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library 85
LC-MS serum proteomics reveals a panel of proteins prognostic of positive responsiveness to bevacizumab therapy in late-stages ovarian cancer patients 84
Development of a novel class of YAP:TEAD interface-3 molecular disruptors to treat colorectal carcinoma 79
Synthesis, characterisation, Hirshfeld surface and in vitro cytotoxicity evaluation of new N-aryl-N0-Alkoxycarbonyl thiocarbamide derivatives. 73
A toolbox of biophysical and analytical assays helps to confirm the activity of novel hTS dimer disrupters (Ddis) with anticancer properties 71
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 71
Structural, Hirshfeld surface and in vitro cytotoxicity evaluation of five new N-aryl-N’-alkoxycarbonyl thiocarbamide derivatives. 68
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth 66
design, synthesis and biological evaluation of novel YAP:TEAD complex disruptors for thetreatment of colorectal cancer 61
Inhibition of cell growth by accumulated spermine is associated with a transient alteration of cell cycle progression 57
Cellular uptake and metabolic degradation of a conjugate of folic acid with an anticancer peptide targeting the human Thymidylate synthase enzyme 55
Telomere Dysfunction Is Associated with Altered {DNA} Organization in Trichoplein/Tchp/Mitostatin ({TpMs}) Depleted Cells 54
Targeting the dimer-monomer equilibrium of thymidylate synthase, to accelerate protein degradation and cancer cell growth inhibition 51
Lead-optimization process and characterization of the dissociative effect applied to new dimer disrupters of human Thymidylate Synthase 50
Development of a sensitive biochemical tool to assess the expression levels of recombinant ectopic proteins in in vitro engineered cellular systems 42
Lead optimization of human thymidylate synthase dimer disrupters: from computational studies to evaluation of their biological profiles 40
Precision medicine through proteomics studies in drug resistant colorectal cancer 32
Integrating MS proteomics in the Medicinal Chemistry pipeline as powerful tool to overcome drug resistance issues in colorectal cancer 31
Structural insight into YAP-TEAD4 protein-protein interactions as target for cancer treatment 30
Dabrafenib-Panobinostat Salt: Improving Dissolution Rate and Inhibition of BRAF Melanoma Cells 28
Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy 18
Totale 14.764
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.802
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.741 0 117 113 254 336 420 480 308 308 106 158 141
2020/20212.822 234 116 202 244 334 176 224 324 133 445 227 163
2021/20221.929 99 121 162 78 100 206 72 90 230 146 402 223
2022/20232.197 239 284 165 235 228 278 82 250 237 32 91 76
2023/20241.790 61 122 119 107 525 202 73 121 31 48 193 188
2024/2025179 164 15 0 0 0 0 0 0 0 0 0 0
Totale 14.764